Literature DB >> 12807380

Sertraline-induced hypomania: a genuine side-effect.

D N Mendhekar1, D Gupta, V Girotra.   

Abstract

OBJECTIVE: Antidepressants including selective serotonin reuptake inhibitor (SSRI)-associated mania or hypomania has been well documented in the literature but these patients with switch have either mood disorders or various risk factors for bipolar disorder. This case report examines SSRI-induced hypomania in a patient with dissociative disorder and highlights hypomania as a genuine side-effect of sertraline rather than a switch.
METHOD: A 23-year-old female patient with dissociative disorder has been described.
RESULTS: Hypomanic symptoms emerged during treatment with sertraline at the dose of 50 mg/day after 3-4 days of initiation of therapy and had complete recovery within 7 days after stopping sertraline.
CONCLUSION: In the absence of risk factors for manic switch, sertraline-induced hypomania may be a true side-effect of drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807380     DOI: 10.1034/j.1600-0447.2003.00080.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  4 in total

Review 1.  Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature.

Authors:  Corey H Allen; Benzi M Kluger; Isabelle Buard
Journal:  Pediatr Neurol       Date:  2017-01-04       Impact factor: 3.372

2.  Childhood dissociation as a precursor of mood disorder: A 5 years follow-up case study.

Authors:  Arnab Bhattacharya; Nishant Goyal; Vinod Kumar Sinha
Journal:  Indian J Psychiatry       Date:  2015 Jan-Mar       Impact factor: 1.759

3.  Bipolar disorder in megalencephalic leukoencephalopathy with subcortical cysts: a case report.

Authors:  Masanori Ishikawa; Yoshie Omachi; Noriko Sato; Eiji Nakagawa
Journal:  BMC Psychiatry       Date:  2020-07-03       Impact factor: 3.630

4.  Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series.

Authors:  Yasunari Yamaguchi; Sohei Kimoto; Takeshi Nagahama; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-17       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.